Fidanacogene elaparvovec is a gene therapy designed to help people with Hemophilia A. It is given through an IV infusion to help the body produce the blood clotting factor that is missing or not working correctly due to the condition.

Giroctocogene fitelparvovec is a gene therapy designed to help people with Hemophilia B. It is given through an IV infusion to help the body produce the blood clotting factor that is missing or not working correctly due to the condition.

Hemophilia A – This is a genetic bleeding disorder caused by a deficiency or lack of clotting factor VIII. Because this protein is missing, the blood cannot clot properly when an injury occurs. Over time, the condition can lead to frequent and spontaneous bleeding into joints and muscles. This repeated bleeding can cause long-term damage to the affected areas.

Hemophilia B – This condition is a genetic disorder resulting from a deficiency of clotting factor IX. The lack of this specific protein prevents the blood from forming clots effectively. As the disease progresses, individuals may experience bleeding episodes in various parts of the body. These episodes can occur following minor injuries or even without a clear cause.